Alessandra Fusco, et al. “Short-Term Cardio-Vascular Risk Score Changes in Type 2 Diabetic Patients on Empaglifozin: A Real-Life Clinical Experience”. Heart Research, vol. 4, no. 3, July 2017, pp. 46-56, doi:10.17140/HROJ-4-141.